| 1. |
- Cicortas Gunnarsson, Lavinia, et al.
(författare)
-
Evolution of a carbohydrate binding module into a protein-specific binder
- 2006
-
Ingår i: Biomolecular Engineering. - : Elsevier BV. - 1389-0344 .- 1878-559X. ; 23:2-3, s. 111-117
-
Tidskriftsartikel (refereegranskat)abstract
- A carbohydrate binding module, CBM4-2, derived front the xylanase (Xyn 10A) of Rhodothermus marinus has been used as a scaffold for molecular diversification. Its binding specificity has been evolved to recognise a quite different target, a human monoclonal IgG4. In order to understand the basis for this drastic change in specificity we have further investigated the target recognition of the IgG4-specific CBMs. Firstly, we defined that the structure target recognised by the selected CBM-variants was the protein and not the carbohydrates attached to the glycoprotein. We also identified key residues involved in the new specificity and/or responsible for the swap in specificity, from xylan to human IgG4. Specific changes present in all these CBMs included mutations not introduced in the design of the library from which the specific clones were selected. Reversion of such mutations led to a complete loss of binding to the target molecule, suggesting that they are critical for the recognition of human IgG4. Together with the mutations introduced at will, they had transformed the CBM scaffold into a protein binder. We have thus shown that the scaffold of CBM4-2 is able to harbour molecular recognition for either carbohydrate or protein structures. (c) 2005 Elsevier B.V. All rights reserved.
|
|
| 2. |
- Delfani, Payam, et al.
(författare)
-
Technical advances of the recombinant antibody microarray technology platform for clinical immunoproteomics
- 2016
-
Ingår i: PLoS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 11:7
-
Tidskriftsartikel (refereegranskat)abstract
- In the quest for deciphering disease-associated biomarkers, high-performing tools for multiplexed protein expression profiling of crude clinical samples will be crucial. Affinity proteomics, mainly represented by antibody-based microarrays, have during recent years been established as a proteomic tool providing unique opportunities for parallelized protein expression profiling. But despite the progress, several main technical features and assay procedures remains to be (fully) resolved. Among these issues, the handling of protein microarray data, i.e. the biostatistics parts, is one of the key features to solve. In this study, we have therefore further optimized, validated, and standardized our in-house designed recombinant antibody microarray technology platform. To this end, we addressed the main remaining technical issues (e.g. antibody quality, array production, sample labelling, and selected assay conditions) and most importantly key biostatistics subjects (e.g. array data pre-processing and biomarker panel condensation). This represents one of the first antibody array studies in which these key biostatistics subjects have been studied in detail. Here, we thus present the next generation of the recombinant antibody microarray technology platform designed for clinical immunoproteomics.
|
|
| 3. |
- Dexlin Mellby, Linda
(författare)
-
Design of antibody microarrays for global profiling of membrane proteins and soluble proteins
- 2010
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Antibody-based microarrays have emerged as an established proteomic technology allowing multiplexed and sensitive profiling of complex proteomes, in a high-throughput and miniaturized manner. Recently, numerous applicative efforts have been pursued generating disease-associated protein signatures that now could be further explored for improved disease diagnostics, prognostics and classification. The aim of this thesis, based on five original papers, was to develop the antibody microarray methodology even further, to allow for global proteome analysis. Accordingly, a miniaturization of the array features was established, allowing for high-density arrays to be fabricated. We showed that sensitive detection of protein analytes in pure system as well as complex serum samples could be achieved using this miniaturized recombinant antibody nanoarray set-up. In additional globalization efforts, we demonstrated that two, novel, recombinant antibody microarray set-ups, based on human scFv antibody fragments, could be designed for membrane protein profiling of intact cells and cell/tissue extracts, respectively. This will provide us with unique and novel means to delineate the membrane proteome, previously proven to be to be difficult to address using conventional proteomic approaches. Taking advantage of these technological developments in a follow-up applicative study, differentially expressed membrane proteins and water-soluble proteins were readily identified in preeclamptic placenta vs. normal placenta. The data showed that candidate disease-associated tissue protein signatures could be identified, that could help to decipher the complex features of preeclampsia at the molecular level. Finally, we demonstrated how a wide variety of protein analytes could be targeted in mantle cell lymphoma, adopting genome-based affinity proteomics, using a novel reverse-phase antibody microarray set-up. Altogether, these technological improvements will allow us to gain further insights into complex molecular pathways in health and disease.
|
|
| 4. |
- Dexlin Mellby, Linda, et al.
(författare)
-
Design of recombinant antibody microarrays for cell surface membrane proteomics
- 2008
-
Ingår i: Journal of Proteome Research. - : American Chemical Society (ACS). - 1535-3893 .- 1535-3907. ; 7:1, s. 319-327
-
Tidskriftsartikel (refereegranskat)abstract
- Generating proteomic maps of membrane proteins, common targets for therapeutic interventions and disease diagnostics, has turned out to be a major challenge. Antibody-based microarrays are among the novel rapidly evolving proteomic technologies that may enable global proteome analysis to be performed. Here, we have designed the first generation of a scaleable human recombinant scFv antibody microarray technology platform for cell surface membrane proteomics as well as glycomics targeting intact cells. The results showed that rapid and multiplexed profiling of the cell surface proteome (and glycome) could be performed in a highly specific and sensitive manner and that differential expression patterns due to external stimuli could be monitored.
|
|
| 5. |
- Dexlin Mellby, Linda, et al.
(författare)
-
Design of recombinant antibody microarrays for membrane protein profiling of cell lysates and tissue extracts.
- 2011
-
Ingår i: Proteomics. - : Wiley. - 1615-9861 .- 1615-9853. ; 11, s. 1550-1554
-
Tidskriftsartikel (refereegranskat)abstract
- Generating global protein expression profiles, including also membrane proteins, will be crucial for our understanding of biological processes in health and disease. In this study, we have expanded our antibody microarray technology platform and designed the first human recombinant antibody microarray for membrane proteins targeting crude cell lysates and tissue extracts. We have optimized all key technological parameters and successfully developed a setup for extracting, labeling and analyzing non-fractionated membrane proteomes under non-denaturing conditions. Finally, the platform was also extended and shown to be compatible with simultaneous profiling of both membrane proteins and water-soluble proteins.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Dexlin Mellby, Linda, et al.
(författare)
-
Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays
- 2010
-
Ingår i: Proteomics Clinical Applications. - : Wiley. - 1862-8354 .- 1862-8346. ; 4:10-11, s. 794-807
-
Tidskriftsartikel (refereegranskat)abstract
- PURPOSE: preeclampsia (PE) is a severe, multi-system pregnancy disorder of yet unknown cause, missing means of treatment, and our fundamental understanding of the disease is still impaired. The purpose of this discovery study was to define candidate placenta tissue protein biomarker signatures to further decipher the molecular features of PE.EXPERIMENTAL DESIGN: we used recombinant antibody microarrays for multiplexed protein expression profiling of preeclamptic placenta tissue (n=25) versus normal placenta (n=11) targeting mainly immunoregulatory water-soluble proteins and membrane proteins. Furthermore, the three known subgroups of PE were profiled, including women with early onset preeclampsia and late onset preeclampsia, as well as women with PE and bilateral notching and intrauterine growth restrictions.RESULTS: the data showed that the first generation of candidate PE-associated placenta tissue protein signatures were delineated, indicating that PE (receiver operating characteristics (ROC) AUC value of 0.83) and the subgroups thereof (ROC AUC values ≤ 0.91) could be distinguished. Notably, the data implied that all subgroups, but preeclampsia with bilateral notching and IUGR, could be further classified into novel subsets (ROC AUC values of 1.0) displaying different inflammatory signatures.CONCLUSIONS AND CLINICAL RELEVANCE: we have taken one step further toward de-convoluting the complex features of PE at the molecular level using affinity proteomics.
|
|
| 10. |
|
|
